Development of an innovative reader and a set of cartridges for the analysis of CBC+ 3DIFF blood cells and markers of inflammation to monitor the health of patients infected with coronavirus, among others. SARS-CoV-2 in remote conditions.
Number_reference_aid_programme: SA.41471(2015/X) Purpose of public aid: Article 25 of Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty That’s it. EU L 187/1 of 26.06.2014).The subject of the project is to carry out R & D work on the development of an innovative reader and a set of cartridges for the analysis of CBC+ 3DIFF blood cells and markers of inflammation (CRP, IL-6, LDH, PCT) to monitor the health of patients infected with, inter alia, Sars-CoV-2 coronavirus. The concept of the planned R & D project responds to the market need, which is primarily to speed up the selection process of patients at risk of severe COVID-19 and those who will be asymptomatic, symptomatic mild or moderate. Offering HomeCyte on the market will make an important contribution to diagnostic reasoning and care for patients with suspected or confirmed SARS-CoV-2 infection and will become the primary tool used in etiological diagnostics, patient monitoring, and epidemiological surveillance. At present, the availability of adequate human and/or infrastructure resources poses significant obstacles to ensuring a timely and effective response to the occurrence of a contagious agent. The project will be carried out in 5 stages, three of which are industrial research, one is development work, and the last stage — pre-implementation works. The direct result of R & D works will be the PoC (PoC) device. Point-of-Care) providing effective analysis of CBC+ 3DIFF blood cells and selected markers of inflammation. The novelty of the result of the project, compared to the offers of competitors of PoC diagnostic devices, should be considered on a global scale. The implementation of the product innovation will take place in its own business of MICROX Sp. z o.o. In the first place, a new product will be offered on the domestic market, and